<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04735471</url>
  </required_header>
  <id_info>
    <org_study_id>ADI-20200101</org_study_id>
    <nct_id>NCT04735471</nct_id>
  </id_info>
  <brief_title>A Study of ADI-001 in B Cell Malignancies</brief_title>
  <acronym>GLEAN-1</acronym>
  <official_title>A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma Delta T Cells in Adults With B Cell Malignancies, in Monotherapy and Combination With IL 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adicet Bio, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adicet Bio, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of ADI-001 in patients with&#xD;
      B cell malignancies. Study details include:&#xD;
&#xD;
      Study Duration: 2 years (1 year of enrollment and 1 year of study participation) Treatment&#xD;
      Duration: ADI-001:1 day (single dose); IL-2 (Part 3 only): 14 days Visit Frequency: Daily for&#xD;
      8 days, then Day 10, 12, 14, 21, 28, and Month 3, 6, 9, and 12&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ADI-001 is an investigational immunotherapy composed of allogeneic gamma delta T cells that&#xD;
      is being evaluated as a potential treatment for patients diagnosed with B cell malignancies&#xD;
      who have relapsed or are refractory to at least two prior regimens. This first-in-human study&#xD;
      will assess the safety and tolerability of ADI-001 and is designed to determine the maximum&#xD;
      tolerated dose (MTD) or optimal dose. Patients will be administered a single infusion of&#xD;
      ADI-001 cells. A combination of ADI-001 and interleukin (IL)-2 may also be evaluated after&#xD;
      the MTD or optimal dose has been determined for the single agent.&#xD;
&#xD;
      The study will also assess the pharmacokinetics and pharmacodynamics of ADI-001.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 4, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>3+3 Factorial Design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Incidence of Subjects with Dose Limiting Toxicities within each dose level cohort</measure>
    <time_frame>Day 28</time_frame>
    <description>This primary endpoint will be used to determine the Maximum Tolerated Dose (MTD) or optimal dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of treatment emergent and treatment related adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>This primary endpoint will be used to determine the optimal dose of ADI-001</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of ADI-001 persistence</measure>
    <time_frame>Day 1 through Month 12</time_frame>
    <description>Defined as duration from Day 1 to undetectable levels of ADI-001 cells per microliter blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate by Lugano Criteria</measure>
    <time_frame>Day 28, Month 3, 6, 9, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response by Lugano Criteria</measure>
    <time_frame>Day 28, Month 3, 6, 9, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival by Lugano Criteria</measure>
    <time_frame>Day 28, Month 3, 6, 9, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Progression by Lugano Criteria</measure>
    <time_frame>Day 28, Month 3, 6, 9, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival by Lugano Criteria</measure>
    <time_frame>Day 28, Month 3, 6, 9, and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Lymphoma, Follicular</condition>
  <condition>Lymphoma, Mantle-Cell</condition>
  <condition>Marginal Zone Lymphoma</condition>
  <condition>Lymphoma, Burkitt</condition>
  <condition>Mediastinal Lymphoma</condition>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <arm_group>
    <arm_group_label>ADI-001 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADI-001 is administered via infusion with ascending dose levels to determine the maximum tolerated dose (MTD) or optimal ADI-001 dose (Part 1).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADI-001 Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADI-001 is administered via infusion to 3 NHL subtypes to confirm dose (Part 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADI-001 in combination with Interleukin-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADI-001 is administered via infusion in combination with subcutaneously administered IL-2 (Part 3).</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>ADI-001</intervention_name>
    <description>Anti-CD20 CAR-T</description>
    <arm_group_label>ADI-001 Dose Escalation</arm_group_label>
    <arm_group_label>ADI-001 Dose Expansion</arm_group_label>
    <arm_group_label>ADI-001 in combination with Interleukin-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Chemotherapy for Lymphodepletion</description>
    <arm_group_label>ADI-001 Dose Escalation</arm_group_label>
    <arm_group_label>ADI-001 Dose Expansion</arm_group_label>
    <arm_group_label>ADI-001 in combination with Interleukin-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Chemotherapy for Lymphodepletion</description>
    <arm_group_label>ADI-001 Dose Escalation</arm_group_label>
    <arm_group_label>ADI-001 Dose Expansion</arm_group_label>
    <arm_group_label>ADI-001 in combination with Interleukin-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Chemotherapy for Lymphodepletion</description>
    <arm_group_label>ADI-001 Dose Escalation</arm_group_label>
    <arm_group_label>ADI-001 Dose Expansion</arm_group_label>
    <arm_group_label>ADI-001 in combination with Interleukin-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-2</intervention_name>
    <description>To support growth and activation of ADI-001</description>
    <arm_group_label>ADI-001 in combination with Interleukin-2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Relapsed/refractory (R/R) previously treated B cell malignancies.&#xD;
&#xD;
          2. Prior treatment must include at least 2 prior regimens, including anti CD20 antibody&#xD;
             therapies.&#xD;
&#xD;
          3. Documented measurable disease as defined by Lugano 2014&#xD;
&#xD;
          4. Male or female â‰¥ 18 years of age&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1&#xD;
&#xD;
          6. Adequate hematological, renal, pulmonary, cardiac, and liver function&#xD;
&#xD;
          7. Resolved toxicities of any prior therapy to either baseline or CTCAE grade 1 (version&#xD;
             5.0)&#xD;
&#xD;
          8. Female patients who are not pregnant or breastfeeding&#xD;
&#xD;
          9. Female patients of childbearing potential and all male patients must agree to use&#xD;
             highly effective methods of birth control for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known CD20-negative B cell lymphoma at time of initial diagnosis&#xD;
&#xD;
          2. Current or history of any of the following conditions:&#xD;
&#xD;
               1. Central nervous system (CNS) primary lymphoma (current or history)&#xD;
&#xD;
               2. Unrelated malignancy requiring systemic treatment (current or history [in the&#xD;
                  past 3 years, other than hormonal treatment which is allowed])&#xD;
&#xD;
          3. Any of the following current conditions:&#xD;
&#xD;
               1. Active acute or chronic graft versus host disease (GvHD) other than grade 1 with&#xD;
                  skin involvement, or GvHD requiring immunosuppressive treatment within 4 weeks of&#xD;
                  enrollment&#xD;
&#xD;
               2. Any other acute or chronic medical or psychiatric condition that may increase the&#xD;
                  risk associated with study participation or investigational product&#xD;
                  administration&#xD;
&#xD;
               3. Tumor mass effects such as bowel obstruction or blood vessel compression that&#xD;
                  require therapy&#xD;
&#xD;
               4. Opportunistic infections&#xD;
&#xD;
          4. History of any clinically significant conditions in the opinion of the Investigator,&#xD;
             including, but not limited to:&#xD;
&#xD;
               1. Infection (including sepsis, pneumonia, bacteremia, fungal, viral and&#xD;
                  opportunistic infections) within 4 weeks prior to first dose of ADI 001&#xD;
&#xD;
               2. Any form of primary immunodeficiency such as severe combined immunodeficiency&#xD;
                  disease&#xD;
&#xD;
               3. Cardiovascular conditions (Class III or IV heart failure as defined by the New&#xD;
                  York Heart Association [NYHA], cardiac angioplasty or stenting, myocardial&#xD;
                  infarction, unstable angina, or other clinically significant cardiac disease)&#xD;
                  within the past 6 months&#xD;
&#xD;
               4. Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura&#xD;
                  within the 4 weeks prior to first dose of ADI 001 or the need for daily&#xD;
                  prednisone greater than 5 mg (or corticosteroid equivalent) to control an&#xD;
                  autoimmune disease&#xD;
&#xD;
               5. Severe immediate hypersensitivity reaction to any of the agents used in this&#xD;
                  study&#xD;
&#xD;
          5. Prior treatment with any of the following:&#xD;
&#xD;
             a Gene therapy, genetically modified cell therapy, or adoptive T cell therapy within 6&#xD;
             weeks of study enrollment. Exception: Prior therapy with approved anti-CD19 CAR T cell&#xD;
             products is allowed.&#xD;
&#xD;
             b Radiation therapy within 4 weeks prior to study entry. Palliative local radiation&#xD;
             may be allowed within 1 week prior to study entry.&#xD;
&#xD;
             c Autologous stem cell transplant (SCT) within 6 weeks of planned ADI 001 infusion d&#xD;
             Allogeneic stem cell transplant and donor lymphocyte infusion within 3 months of&#xD;
             planned CAR T cell infusion&#xD;
&#xD;
          6. Patients unwilling to participate in an extended safety monitoring period (long term&#xD;
             follow up [LTFU] protocol)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rose Lai, MD</last_name>
    <role>Study Director</role>
    <affiliation>Adicet Bio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rose Lai</last_name>
    <phone>(650) 850-8020</phone>
    <email>clinicaltrials@adicetbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Davina Moussa</last_name>
    <email>dmoussa@adicetbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University Medical Centr</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Miklos, MD</last_name>
      <phone>650-723-0822</phone>
      <email>dmiklos@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Don A Stevens, MD</last_name>
      <phone>502-899-3366</phone>
      <email>Don.Stevens@nortonhealthcare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Houston Holmes, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sattva Neelapu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehdi Hamadani, MD</last_name>
      <phone>414-805-0505</phone>
      <email>mhamadani@mcw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>January 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasms</keyword>
  <keyword>Lymphoproliferative Disorders</keyword>
  <keyword>Lymphatic Diseases</keyword>
  <keyword>Immunoproliferative Disorders</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Bendamustine</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Interleukin-2</keyword>
  <keyword>T cells,gamma delta</keyword>
  <keyword>Immunotherapy, Adoptive</keyword>
  <keyword>Antigens, CD20</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

